Female doctor talking to female patient, Clinical genomics, blood cancer, oncology
Oncology | Blood Cancer

Sensitive JAK2 V617F mutation detection, whenever you need it

Give oncologist-hematologists results they can trust

JAK2 in MPNs

Nearly all patients with a myeloproliferative neoplasm (MPN) has a mutation in the Janus kinase 2 (JAK2) gene.*  JAK2 V617F mutation is found in >95% of polycythemia vera (PV) cases, and in approximately 60% of essential thrombocythemia (ET) and primary myelofibrosis (PMF) cases.**

The JAK2 V617F mutation, in particular, plays a central role and is a major diagnostic criterion for MPN in the WHO 2016 guidelines.***

Testing for clinically relevant biomarkers like the JAK2 V617F can help oncologist-hematologists accurately diagnose MPNs and make better informed decisions on their management.

Onco hematology, Leukemia, Chemotherapy, Patient, Doctor, Cancer
Reliably detect JAK2 V617F

Our ipsogen JAK2 solutions let you design and maintain your JAK2 detection assay easily.

With the ipsogen® JAK2 RGQ PCR Kit, you can be sure of:

  • Reliable qualitative and quantitative detection
  • Simple and automated JAK2 V617F results interpretation
  • An easy, ready-to-use workflow that saves time and lowers costs
  • Increased lab efficiency
  • FDA-clearance and compliance with IVDR (EU) 2017/746

Browse our region-specific JAK2 tests

Confident JAK2 V617F detection and quantification

Our IVDR-compliant ipsogen JAK2 RGQ PCR Kit is for the detection and quantification of the JAK2 V617F/G1849T allele as an adjunct to evaluation of suspected Ph- MPN and molecular disease monitoring in MPN patients.

With its robustness and established clinical performance, the ipsogen JAK2 RGQ PCR Kit lets you:

  • Follow diagnostic algorithm testing and WHO 2016 guidelines by reliably testing clinically relevant MPN biomarkers
  • Save time and increase lab efficiency
  • Access direct results interpretation and reporting
Blood cancer content world, female doctor talking to patient, Clinical genomics, oncology
Questions about IVDR and our JAK2 solution?
The go-to resource for all you need to know about how IVDR affects our JAK2 solution.
Read it
References:

* Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation (2006). https://ashpublications.org/blood/article/108/10/3548/22733/Mutation-of-JAK2-in-the-myeloproliferative (accessed May 10, 2022)

** Myeloproliferative Neoplasms: A Contemporary Review (2015). https://jamanetwork.com/journals/jamaoncology/fullarticle/2194736 (accessed May 10, 2022)

*** The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia (2016). https://ashpublications.org/blood/article/127/20/2391/35255/The-2016-revision-to-the-World-Health-Organization (accessed May 10, 2022)